A genome-wide association study of marginal zone lymphoma shows association to the HLA region
Joseph Vijai(Memorial Sloan Kettering Cancer Center), Zhaoming Wang(National Cancer Institute), Sonja I. Berndt(National Cancer Institute), Christine F. Skibola(Berkeley Public Health Division), Susan L. Slager(Mayo Clinic in Florida), Sílvia de Sanjosé(Institut d'Investigació Biomédica de Bellvitge), Mads Melbye(Statens Serum Institut), Bengt Glimelius(Karolinska University Hospital), Paige M. Bracci(University of California, San Francisco), Lucía Conde(Berkeley Public Health Division), Brenda M. Birmann(Brigham and Women's Hospital), Sophia Wang(City Of Hope National Medical Center), Angela Brooks‐Wilson(BC Cancer Agency), Qing Lan(National Cancer Institute), Paul I. W. de Bakker(University Medical Center Utrecht), Roel Vermeulen(Utrecht University), Carol S. Portlock(Memorial Sloan Kettering Cancer Center), Stephen M. Ansell(Mayo Clinic), Brian K. Link(University of Iowa), Jacques Riby(Berkeley Public Health Division), Kari E. North(University of North Carolina at Chapel Hill), Jian Gu(The University of Texas MD Anderson Cancer Center), Henrik Hjalgrim(Statens Serum Institut), Wendy Cozen(University of Southern California), Nikolaus Becker(German Cancer Research Center), Lauren R. Teras(American Cancer Society), John J. Spinelli(BC Cancer Agency), Jennifer Turner(Douglass Hanly Moir Pathology), Yawei Zhang(Yale University), Mark P. Purdue(National Cancer Institute), Graham G. Giles(Cancer Council Victoria), Rachel S. Kelly(Imperial College London), Anne Zeleniuch‐Jacquotte(New York University), Maria Grazia Ennas(University of Cagliari), Alain Monnereau(Inserm), Kimberly A. Bertrand(Brigham and Women's Hospital), Demetrius Albanes(National Cancer Institute), Tracy Lightfoot(University of York), Meredith Yeager(National Cancer Institute), Charles C. Chung(National Cancer Institute), Laurie Burdett(National Cancer Institute), Amy Hutchinson(National Cancer Institute), Charles Lawrence(Westat (United States)), Rebecca Montalvan(Westat (United States)), Liming Liang(Massachusetts Department of Public Health), Jinyan Huang(Harvard University), Baoshan Ma(Harvard University), Danylo Villano(Memorial Sloan Kettering Cancer Center), Ann Maria(Memorial Sloan Kettering Cancer Center), Marina Corines(Memorial Sloan Kettering Cancer Center), Tinu Thomas(Memorial Sloan Kettering Cancer Center), Anne J. Novak(Mayo Clinic), Ahmet Doǧan(Memorial Sloan Kettering Cancer Center), Mark Liebow(Mayo Clinic), Carrie A. Thompson(Mayo Clinic), Thomas E. Witzig(Mayo Clinic), Thomas M. Habermann(Mayo Clinic), George J. Weiner(University of Iowa), Martyn T. Smith(Berkeley Public Health Division), Elizabeth A. Holly(University of California, San Francisco), Rebecca D. Jackson(The Ohio State University), Lesley F. Tinker(Fred Hutch Cancer Center), Yuanqing Ye(The University of Texas MD Anderson Cancer Center), Hans‐Olov Adami(Harvard University), Karin E. Smedby(Karolinska Institutet), Anneclaire J. De Roos(Fred Hutch Cancer Center), Patricia Hartge(National Cancer Institute), Lindsay M. Morton(National Cancer Institute), Richard K. Severson(Wayne State University), Yolanda Benavente(Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública), Paolo Boffetta(Tisch Hospital), Paul Brennan(Centre international de recherche sur le cancer), Lenka Foretová(Masaryk Memorial Cancer Institute), Marc Maynadié(Université de Bourgogne), James McKay(Centre international de recherche sur le cancer), Anthony Staines(Dublin City University), W. Ryan Diver(American Cancer Society), Claire M. Vajdic(UNSW Sydney), Bruce K. Armstrong(The University of Sydney), Anne Kricker(The University of Sydney), Tongzhang Zheng(Yale University), Theodore R. Holford(Yale University), Gianluca Severi(The University of Melbourne), Paolo Vineis(Health Foundation), Giovanni Maria Ferri(University of Bari Aldo Moro), R Ricco(University of Bari Aldo Moro), Lucia Miligi(Prevention Institute), Jacqueline Clavel(Université Paris-Sud), Edward Giovannucci(Brigham and Women's Hospital), Peter Kraft(Massachusetts Department of Public Health), Jarmo Virtamo(Finnish Institute for Health and Welfare), Alex Smith(University of York), Eleanor Kane(University of York), Eve Roman(University of York), Brian C.‐H. Chiu(Chicago Department of Public Health), Joseph F. Fraumeni(National Cancer Institute), Xifeng Wu(The University of Texas MD Anderson Cancer Center), James R. Cerhan(Mayo Clinic in Florida), Kenneth Offit(Memorial Sloan Kettering Cancer Center), Stephen J. Chanock(National Cancer Institute), Nathaniel Rothman(National Cancer Institute), Alexandra Nieters(University Medical Center Freiburg)
Cited by 68Open Access
Abstract
Marginal zone lymphoma (MZL) is the third most common subtype of B-cell non-Hodgkin lymphoma. Here we perform a two-stage GWAS of 1,281 MZL cases and 7,127 controls of European ancestry and identify two independent loci near BTNL2 (rs9461741, P=3.95 × 10(-15)) and HLA-B (rs2922994, P=2.43 × 10(-9)) in the HLA region significantly associated with MZL risk. This is the first evidence that genetic variation in the major histocompatibility complex influences MZL susceptibility.
Related Papers
No related papers found
Powered by citation graph analysis